Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
June 09, 2023 18:25 ET
|
Allogene Therapeutics, Inc.
Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous TherapiesPresentation...
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2023 09:00 ET
|
Allogene Therapeutics, Inc.
Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation...
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
May 24, 2023 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
May 11, 2023 11:50 ET
|
Allogene Therapeutics, Inc.
Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) --...
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
May 03, 2023 16:02 ET
|
Allogene Therapeutics, Inc.
Enrollment Ongoing in Industry’s First Potentially Pivotal Phase 2 Allogeneic CAR T Trial, ALPHA2, in Relapsed/Refractory Large B Cell LymphomaInitiated Phase 2 EXPAND Trial to Support Licensure of...
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023 10:06 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
April 25, 2023 08:30 ET
|
Allogene Therapeutics, Inc.
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
April 20, 2023 16:05 ET
|
Allogene Therapeutics, Inc.
Former Kite Pharma Executive Responsible for the Development and Commercial Launch of Two of the Most Successful Autologous CAR T Manufacturing Processes in the IndustryBrings Unique Experience as a...
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
April 17, 2023 10:15 ET
|
Allogene Therapeutics, Inc.
Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting TherapySingle...
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
April 13, 2023 08:30 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...